Our product pipeline focuses on autoimmune disorders and solid tumors. We are aggressively applying our BAFF CAR to autoimmune disorders and multiple dual targeting CAR optimization designs towards breaking down the barriers of CAR T in the treatments of solid tumors.

We believe our allogeneic platform will fundamentally change access and affordability of CAR T therapies. Here’s our progress towards making that a reality.